Literature DB >> 28724800

Siglec-G represses DAMP-mediated effects on T cells.

Tomomi Toubai1, Corinne Rossi1, Katherine Oravecz-Wilson1, Cynthia Zajac1, Chen Liu2, Thomas Braun3, Hideaki Fujiwara1, Julia Wu1, Yaping Sun1, Stuart Brabbs1, Hiroya Tamaki4, John Magenau1, Pang Zheng5, Yang Liu5, Pavan Reddy1.   

Abstract

The role of negative regulators or suppressors of the damage-associated molecular pattern-mediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell-dependent immunopathology remain unknown. Sialic acid-binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell-autonomous role is unknown. Utilizing loss-of-function-based (genetic knockout) and gain-of-function-based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell-autonomous role is critical for modulating the severity of the T cell-mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.

Entities:  

Keywords:  Immunology; Transplantation

Year:  2017        PMID: 28724800      PMCID: PMC5518560          DOI: 10.1172/jci.insight.92293

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  40 in total

1.  Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells.

Authors:  Matthew S Macauley; James C Paulson
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

Review 2.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

3.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

4.  Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease.

Authors:  Tomomi Toubai; Yaping Sun; Isao Tawara; Ann Friedman; Chen Liu; Rebecca Evers; Evelyn Nieves; Chelsea Malter; Peter Chockley; Ivan Maillard; Susan Winandy; Pavan Reddy
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

Review 5.  TLR-dependent T cell activation in autoimmunity.

Authors:  Kingston H G Mills
Journal:  Nat Rev Immunol       Date:  2011-11-18       Impact factor: 53.106

6.  A novel role for the semaphorin Sema4D in the induction of allo-responses.

Authors:  Raimon Duran-Struuck; Isao Tawara; Kathi Lowler; Shawn G Clouthier; Elizabeth Weisiger; Clare Rogers; Gary Luker; Atsushi Kumanogoh; Chen Liu; James L M Ferrara; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-21       Impact factor: 5.742

7.  CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns.

Authors:  Yang Liu; Guo-Yun Chen; Pan Zheng
Journal:  Trends Immunol       Date:  2009-09-26       Impact factor: 16.687

8.  CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.

Authors:  Guo-Yun Chen; Jie Tang; Pan Zheng; Yang Liu
Journal:  Science       Date:  2009-03-05       Impact factor: 47.728

9.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

Authors:  Tomomi Toubai; Guoqing Hou; Nathan Mathewson; Chen Liu; Ying Wang; Katherine Oravecz-Wilson; Emily Cummings; Corinne Rossi; Rebecca Evers; Yaping Sun; Julia Wu; Sung Won Choi; Dexing Fang; Pan Zheng; Yang Liu; Pavan Reddy
Journal:  Blood       Date:  2014-04-02       Impact factor: 22.113

View more
  16 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Authors:  Michal A Stanczak; Shoib S Siddiqui; Marcel P Trefny; Daniela S Thommen; Kayluz Frias Boligan; Stephan von Gunten; Alexandar Tzankov; Lothar Tietze; Didier Lardinois; Viola Heinzelmann-Schwarz; Michael von Bergwelt-Baildon; Wu Zhang; Heinz-Josef Lenz; Younghun Han; Christopher I Amos; Mohammedyaseen Syedbasha; Adrian Egli; Frank Stenner; Daniel E Speiser; Ajit Varki; Alfred Zippelius; Heinz Läubli
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

3.  CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.

Authors:  Xu Wang; Mingyue Liu; Jifeng Zhang; Nicholas K Brown; Peng Zhang; Yan Zhang; Heng Liu; Xuexiang Du; Wei Wu; Martin Devenport; Weng Tao; Yang Mao-Draayer; Guo-Yun Chen; Y Eugene Chen; Pan Zheng; Yang Liu
Journal:  Cell Metab       Date:  2022-08-02       Impact factor: 31.373

Review 4.  Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.

Authors:  Suze A Jansen; Edward E S Nieuwenhuis; Alan M Hanash; Caroline A Lindemans
Journal:  Mucosal Immunol       Date:  2022-06-02       Impact factor: 8.701

5.  Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.

Authors:  Zihan Wang; Zihan Geng; Wenwei Shao; Enyang Liu; Jingxuan Zhang; Jingshu Tang; Pingzhang Wang; Xiuyuan Sun; Lin Xiao; Weiyan Xu; Youhui Zhang; Heng Cui; Liang Zhang; Xi Yang; Xiaohong Chang; Xiaoyan Qiu
Journal:  Cell Mol Immunol       Date:  2019-11-21       Impact factor: 22.096

6.  miR29a and miR378b Influence CpG-Stimulated Dendritic Cells and Regulate cGAS/STING Pathway.

Authors:  Abid Ullah Shah; Yanan Cao; Naila Siddique; Jian Lin; Qian Yang
Journal:  Vaccines (Basel)       Date:  2019-11-26

7.  Selective Response to Bacterial Infection by Regulating Siglec-E Expression.

Authors:  Yin Wu; Darong Yang; Runhua Liu; Lizhong Wang; Guo-Yun Chen
Journal:  iScience       Date:  2020-08-20

Review 8.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

Review 9.  Untangling Local Pro-Inflammatory, Reparative, and Regulatory Damage-Associated Molecular-Patterns (DAMPs) Pathways to Improve Transplant Outcomes.

Authors:  Gaelen K Dwyer; Hēth R Turnquist
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

10.  CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Authors:  Yuichi Ozawa; Yuhei Harutani; Jun Oyanagi; Hiroaki Akamatsu; Eriko Murakami; Ryota Shibaki; Atsushi Hayata; Takeya Sugimoto; Masanori Tanaka; Toshiaki Takakura; Katsuyuki Furuta; Yuka Okuda; Kouichi Sato; Shunsuke Teraoka; Hiroki Ueda; Nahomi Tokudome; Yuka Kitamura; Junya Fukuoka; Masanori Nakanishi; Yasuhiro Koh; Nobuyuki Yamamoto
Journal:  Cancer Sci       Date:  2020-11-27       Impact factor: 6.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.